Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression
文献类型：期刊论文
| 作者 | Hu, Zonglong2,3; Wei, Fan3; Su, Yi3; Wang, Yafang3; Shen, Yanyan3; Fang, Yanfen3; Ding, Jian1,2,3 ; Chen, Yi(1.2)
|
| 刊名 | Signal Transduction and Targeted Therapy
 |
| 出版日期 | 2023-01-06 |
| 卷号 | 8期号:2页码:692-704 |
| ISSN号 | 2095-9907 |
| DOI | 10.1038/s41392-022-01221-6 |
| 文献子类 | Article |
| 英文摘要 | Histone deacetylase (HDAC) is a kind of protease that modifies histone to regulate gene expression,and is usually abnormally activated in tumors.The approved pan-HDAC inhibitors have demonstrated clinical benefits for patients in some hematologic malignancies.Only limited therapeutic success in breast cancer has been observed in clinical trials.In this study,we declare that pan-HDAC inhibitors targeting NEDD9-FAK pathway exacerbate breast cancer metastasis in preclinical models,which may severely impede their clinical success.NEDD9 is not an oncogene,however,it has been demonstrated recently that there are high level or activity changes of NEDD9 in a variety of cancer,including leukemia,colon cancer,and breast cancer.Mechanistically,pan-HDAC inhibitors enhance H3K9 acetylation at the nedd9 gene promoter via inhibition of HDAC4 activity,thus increase NEDD9 expression,and then activate FAK phosphorylation.The realization that pan-HDAC inhibitors can alter the natural history of breast cancer by increasing invasion warrants clinical attention.In addition,although NEDD9 has been reported to have a hand in breast cancer metastasis,it has not received much attention,and no therapeutic strategies have been developed.Notably,we demonstrate that FAK inhibitors can reverse breast cancer metastasis induced by upregulation of NEDD9 via pan-HDAC inhibitors,which may offer a potential combination therapy for breast cancer. |
| 语种 | 英语 |
| CSCD记录号 | CSCD:7412964 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/309629]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Ding, Jian |
| 作者单位 | 1.State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China 2.University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, China; 3.Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; |
| 推荐引用方式 GB/T 7714 | Hu, Zonglong,Wei, Fan,Su, Yi,et al. Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression[J]. Signal Transduction and Targeted Therapy,2023,8(2):692-704. |
| APA | Hu, Zonglong.,Wei, Fan.,Su, Yi.,Wang, Yafang.,Shen, Yanyan.,...&Chen, Yi.(2023).Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression.Signal Transduction and Targeted Therapy,8(2),692-704. |
| MLA | Hu, Zonglong,et al."Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression".Signal Transduction and Targeted Therapy 8.2(2023):692-704. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。